<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glomerulopathy with fibronectin deposits</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glomerulopathy with fibronectin deposits</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glomerulopathy with fibronectin deposits</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Several glomerular disorders result from the deposition or accumulation of proteins within glomeruli that disrupt glomerular structure and function. One of these disorders is glomerulopathy with fibronectin deposits (GFND), also known as fibronectin glomerulopathy, which is a rare, familial glomerular disease caused by the deposition of fibronectin and other matrix-type proteins in glomeruli. Ultrastructurally, the deposits are electron-dense and usually homogenous to finely granular, occasionally showing fibrillar substructure.</p><p>GFND will be reviewed here. Other glomerular disorders resulting from the deposition or accumulation of proteins within glomeruli, including amyloidosis, fibrillary glomerulonephritis, immunotactoid glomerulonephritis, and lipoprotein glomerulopathy, are presented in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3120.html" rel="external">"Renal amyloidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3115.html" rel="external">"Glomerular diseases due to nonamyloid fibrillar deposits"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3088.html" rel="external">"Lipoprotein glomerulopathy"</a>.)</p><p></p><p class="headingAnchor" id="H3732486058"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Glomerulopathy with fibronectin deposits (GFND) is rare. The disorder has a slight male predominance and has been described mainly in White and Asian individuals [<a href="#rid1">1-4</a>]. Cases in Black or Hispanic patients have yet to be reported. Although most reported cases have been familial, sporadic cases may occur. As an example, one Chinese patient was described with a typical Y973C mutation of the fibronectin gene [<a href="#rid5">5</a>], but neither parent had this mutation. Another young Indian woman presented with nephrotic-range proteinuria, a low serum complement C3 level, and what appeared to be a rapidly progressive disease course that was diagnosed as GFND by kidney biopsy [<a href="#rid6">6</a>]. No one in her family had kidney disease, and no mutations were found by exon sequencing of her fibronectin gene. This was, however, a very atypical presentation for GFND.</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H3"><span class="h2">Biology of fibronectin</span><span class="headingEndMark"> — </span>Fibronectin is a large, dimeric glycoprotein consisting of two similar subunits (approximately 250 kDa in weight). It functions as an adhesive glycoprotein, aiding in branching morphogenesis, cellular proliferation, wound healing, phagocytosis, platelet-platelet cohesion that is mediated in part by binding to the glycoprotein IIb/IIIa receptor, and thrombus formation [<a href="#rid7">7-9</a>].</p><p>Fibronectin normally exists in a soluble or plasma form (which circulates in blood) and an insoluble or cellular form (which is seen in basement membranes and extracellular matrices).</p><p class="headingAnchor" id="H4"><span class="h2">Fibronectin deposition</span><span class="headingEndMark"> — </span>Although fibronectin is found in the normal glomerular mesangial matrix, enhanced fibronectin accumulation is variably observed in several different glomerulopathies, including diabetic nephropathy and lupus nephritis [<a href="#rid10">10-17</a>]. The increase in fibronectin expression in these diseases is secondary to locally stimulated mesangial and epithelial cell production of the insoluble or cellular form.</p><p>By comparison, glomerulopathy with fibronectin deposits (GFND) is associated with accumulation of fibronectin that is mainly derived from the soluble plasma isoform. This was shown in a study in which the relative amounts of the two different isoforms of fibronectin were quantified by two antibodies, one of which detected both cellular and plasma fibronectins, and the other detected only the cellular form [<a href="#rid18">18</a>]. Investigators examined six unrelated families with GFND and kidney biopsy specimens from a total of 15 patients, as well as nine patients from four other previously reported families. Affected patients had predominant fibronectin deposits, with strong staining using the antibody against both the plasma and cellular forms but weak staining using the antibody against the cellular form.</p><p>Recurrent disease in kidney allografts of patients who were transplanted for end-stage kidney disease (ESKD) due to GFND supports the hypothesis that kidney accumulation of fibronectin is most likely due to an underlying abnormality in circulating plasma fibronectin:</p><p class="bulletIndent1"><span class="glyph">●</span>GFND recurred within four months in a 52-year-old woman who presented with proteinuria and reduced kidney function [<a href="#rid19">19</a>]. The patient had a biopsy suggestive of recurrent GFND 19 days after transplantation, although specialized staining to confirm recurrence was not performed at that time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence was observed in a patient in whom a kidney allograft biopsy performed 23 months after transplantation revealed the typical histologic features of GFND [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another patient had approximately 14 years of adequate kidney function from a cadaveric kidney prior to biopsy-confirmed recurrent disease in the allograft [<a href="#rid21">21</a>].</p><p></p><p>It is unclear why fibronectin is deposited in these cases. Theoretically, fibronectin may be complexed with other proteins. Immunoglobulins do not appear to be involved, as they are generally not seen by immunohistochemical analysis. Proteomic analysis of glomeruli removed from kidney biopsies of patients with GFND by laser capture microscopy showed that, in addition to various isoforms of fibronectin, the deposits contained large amounts of the matrix proteins fibulin-1 and fibulin-5 [<a href="#rid22">22</a>]. This finding was unique to the deposits of GFND. Fibulins were not expressed to a significant extent in normal glomeruli, Kimmelstiel-Wilson nodules of diabetic nephropathy, or in wire-loop lesions of lupus nephritis [<a href="#rid22">22</a>].</p><p>Fibulins bind to fibronectin and regulate several functions of fibronectin, including those related to cell shape, motility, and adhesion [<a href="#rid23">23,24</a>]. It is possible that fibulin-fibronectin complexes disrupt normal, fibronectin-dependent mesangial and/or podocyte motility, adhesion, and spreading, resulting in the characteristic clinical features. (See <a class="local">'Clinical manifestations'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>Analysis of family clusters indicates autosomal dominant transmission of the genetic defect in glomerulopathy with fibronectin deposits (GFND), with age-related penetrance [<a href="#rid20">20</a>]. Linkage to the fibronectin gene <em>FN1 </em>was noted in several Italian and Japanese pedigrees [<a href="#rid1">1-3</a>]. In one family with eight affected subjects, for example, missense mutations in <em>FN1</em> were detected and then identified in 6 of 15 unrelated pedigrees (40 percent) with GFND [<a href="#rid1">1</a>]. Although mutations in <em>FN1</em> may be necessary for GFND to develop, they are not sufficient, since not all family members with the mutation develop clinical kidney disease [<a href="#rid3">3,22</a>].</p><p>Functional studies of mutant fibronectin fragments have revealed decreased binding to glomerular endothelial cells and podocytes and reduced ability to induce endothelial cell spreading and cytoskeletal reorganization compared with wild-type fragments [<a href="#rid1">1</a>]. However, these results depend upon how the mutants were constructed [<a href="#rid3">3</a>]. In studies using full-length fibronectin constructs, several <em>FN1</em> gene mutations found in patients with GFND have had only minimal effects on protein conformation and matrix formation [<a href="#rid25">25</a>]. Analysis of an <em>FN1</em> mutation causing the deletion of an isoleucine residue and GFND in a father and son suggested that this mutation probably disrupts the beta sheet conformation of fibronectin in the vicinity of the lost amino acid, affecting proper folding and impairing functional activity [<a href="#rid26">26</a>]. Prior studies in animal models suggested a possible role for the gene for uteroglobin, a protein that binds with high affinity to fibronectin [<a href="#rid27">27,28</a>]. However, the uteroglobin gene was eventually excluded as causative for human disease [<a href="#rid29">29,30</a>]. Thus, it remains unclear how changes in <em>FN1</em> result in glomerular fibronectin deposition.</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Glomerulopathy with fibronectin deposits (GFND) is characterized clinically by varying degrees of proteinuria, which is typically first seen between the ages of 20 and 40 years [<a href="#rid20">20</a>]. This is followed, over the next 15 to 20 years, by hypertension, microscopic hematuria, and in most patients, slow progression to end-stage kidney disease (ESKD). Complement levels are normal. GFND is rarely rapidly progressive [<a href="#rid31">31</a>].</p><p>In one of the largest studies, the clinical features of 23 affected patients were reported [<a href="#rid18">18</a>]. Eight of 16 in whom a 24-hour urine specimen was obtained at the time of diagnostic biopsy had more than 3 g of proteinuria. Microscopic hematuria and hypertension were observed in 12 and 10 patients, respectively. The mean plasma creatinine measured at the time of biopsy in 16 patients was 1.1 mg/dL (97.2 micromol/L). Among the patients in whom follow-up was available, four patients had normal kidney function, six had slowly progressive kidney function impairment, five were undergoing dialysis (range from time of biopsy was 2 to 13 years), and four had received a kidney allograft.</p><p>There also may be an association with hyperkalemic distal renal tubular acidosis [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">HISTOPATHOLOGIC FINDINGS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The first histologic examinations of glomerulopathy with fibronectin deposits (GFND) described enlarged glomeruli with minimal hypercellularity and the presence of large deposits in the glomerular capillaries [<a href="#rid21">21,32,33</a>]. In a patient with an appropriate clinical presentation, a family history of kidney disease, and histologic features as described in the ensuing sections, immunohistochemistry showing staining for fibronectin in the mesangium and along the capillary walls confirms the diagnosis. Glomeruli may also be microdissected from a kidney biopsy and submitted for proteomic analysis (mass spectrometry) to confirm a diagnosis of GFND [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Light microscopy</span><span class="headingEndMark"> — </span>Light microscopy shows glomerular enlargement and usually some evidence of minimal cellular proliferation, producing a lobular or clover-like appearance that may be confused with membranoproliferative glomerulonephritis (MPGN). The glomerular capillary walls may be thickened and the mesangium greatly expanded by acellular periodic acid-Schiff (PAS)-positive homogeneous material that can result in severely narrowed capillary lumina. Staining with Congo red or methenamine silver is consistently negative (<a class="graphic graphic_picture graphicRef86699" href="/d/graphic/86699.html" rel="external">picture 1</a>).</p><p>There is no consistent specific tubulointerstitial compartment abnormality. However, interstitial fibrosis and tubular atrophy become more prominent over time, a common finding in progressive kidney disease. In one case report, a patient diagnosed with GFND as a child had a repeat kidney biopsy 10 years later when kidney function deteriorated and was found to have plasma fibronectin (by immunochemistry) in extraglomerular arterioles [<a href="#rid34">34,35</a>]. The blood vessels had severely narrowed lumina, and the patient presented with severe hypertension and hemolytic anemia.</p><p class="headingAnchor" id="H10"><span class="h2">Electron microscopy</span><span class="headingEndMark"> — </span>Electron microscopy typically reveals large to massive nondescript, electron-dense subendothelial and mesangial deposits. The deposits have been described as finely granular or fibrillar in some cases. If fibrillar, the fibrils are approximately 12 nm in width and 125 nm in length and are typically arranged in an irregular fashion. These fibrils are slightly wider than those seen in amyloid (8 to 10 nm). However, they are thinner than the fibrils in fibrillary glomerulonephritis (18 to 22 nm) and the microtubules of immunotactoid glomerulopathy (greater than 30 nm) (<a class="graphic graphic_picture graphicRef86700" href="/d/graphic/86700.html" rel="external">picture 2</a>) [<a href="#rid36">36</a>].</p><p>A case of GFND without the typical large mesangial and subendothelial fibronectin deposits has been described [<a href="#rid37">37</a>]. Instead, this patient had thin glomerular basement membranes and increased fibronectin staining of the glomerular capillaries associated with a novel gain-of-function mutation in <em>FN1</em> (c.3415G&gt;A). This variant fibronectin induced beta1 integrin overexpression in glomeruli and bound poorly to collagen IV A3 and A4.</p><p class="headingAnchor" id="H11"><span class="h2">Immunofluorescence</span><span class="headingEndMark"> — </span>Immunoglobulin and complement component staining is absent or weak in GFND. Immunohistochemistry examination showing staining for fibronectin in the mesangium and along the capillary walls confirms the diagnosis (<a class="graphic graphic_picture graphicRef88601" href="/d/graphic/88601.html" rel="external">picture 3</a>). It is the plasma isoform of fibronectin that stains most intensely [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The optimal treatment for glomerulopathy with fibronectin deposits (GFND) is uncertain. There are no high-quality data regarding the use of immunomodulating agents, plasmapheresis, or any other specific therapy aimed at the underlying disease. One case report demonstrated a reduction of proteinuria in a patient with GFND after a six-month course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid38">38</a>]. Glucocorticoids cannot be generally recommended for all patients with GFND but may be considered on an individual basis.</p><p>The most appropriate option is probably the use of nonspecific treatment methods intended to prolong adequate kidney function. This includes strict control of the blood pressure and proteinuria, usually with the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">End-stage kidney disease</span><span class="headingEndMark"> — </span>In general, the management of patients who develop end-stage kidney disease (ESKD) due to GFND is similar to that in other types of kidney disease. These patients are good candidates for all forms of kidney replacement therapy. Hemodialysis, peritoneal dialysis, and kidney transplantation have all been used with good success. As previously mentioned, there have been case reports of disease recurrence in transplanted patients, sometimes within the first year after transplantation [<a href="#rid19">19,20,39</a>]. However, the true risk for recurrent disease in kidney allograft is not known.</p><p class="headingAnchor" id="H2082249595"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H1037702"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Glomerulopathy with fibronectin deposits (GFND), also known as fibronectin glomerulopathy, is a rare, autosomal dominant, inherited glomerular disease associated with the massive deposition of the glycoprotein fibronectin. It is most likely caused by an underlying abnormality in circulating plasma fibronectin. (See <a class="local">'Introduction'</a> above and <a class="local">'Fibronectin deposition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Clinical characteristics include the onset of proteinuria between the ages of 20 and 40 years. This is followed by hypertension, microscopic hematuria, and slow progression to end-stage kidney disease (ESKD) over the next 15 to 20 years. Complement levels are normal. There may be an association with hyperkalemic distal renal tubular acidosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnosis is made only by kidney biopsy. No clinical or laboratory findings are characteristic. The diagnosis is suggested by the presence of large, finely granular, electron-dense deposits. The diagnosis is confirmed by the demonstration of fibronectin staining by immunohistochemistry or glomerular proteomics. (See <a class="local">'Histopathologic findings and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The optimal treatment is uncertain. There are no high-quality data regarding the use of immunomodulating agents, plasmapheresis, or any other specific therapy. Nonspecific therapies that may prolong kidney function include strict control of the blood pressure and the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-stage kidney disease</strong> – The management of patients who develop ESKD is similar to that in other types of kidney disease. These patients are candidates for all forms of kidney replacement therapy, including transplantation. There have been case reports of disease recurrence in transplanted patients. However, the true risk for recurrent disease in kidney allograft is not well understood. (See <a class="local">'End-stage kidney disease'</a> above.)</p><p></p><p class="headingAnchor" id="H305622813"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Simon Prince, DO, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Castelletti F, Donadelli R, Banterla F, et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 2008; 105:2538.</a></li><li><a class="nounderline abstract_t">Ertoy Baydar D, Kutlugun AA, Bresin E, Piras R. A case of familial glomerulopathy with fibronectin deposits caused by the Y973C mutation in fibronectin. Am J Kidney Dis 2013; 61:514.</a></li><li><a class="nounderline abstract_t">Ohtsubo H, Okada T, Nozu K, et al. Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits. Pediatr Nephrol 2016; 31:1459.</a></li><li><a class="nounderline abstract_t">Chen H, Bao H, Xu F, et al. Clinical and morphological features of fibronectin glomerulopathy: a report of ten patients from a single institution. Clin Nephrol 2015; 83:93.</a></li><li><a class="nounderline abstract_t">Li C, Wen YB, Li H, et al. Fibronectin Glomerulopathy Caused by the Y973C Mutation in Fibronectin: A Case Report and Literature Review. Chin Med Sci J 2018; 33:60.</a></li><li><a class="nounderline abstract_t">Mandal SN, Shrivastava S, Piras R, Gowrishankar S. Fibronectin glomerulopathy - A sporadic case with unusual clinical manifestation. Saudi J Kidney Dis Transpl 2017; 28:1416.</a></li><li><a class="nounderline abstract_t">Sakai T, Larsen M, Yamada KM. Fibronectin requirement in branching morphogenesis. Nature 2003; 423:876.</a></li><li><a class="nounderline abstract_t">Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A 2003; 100:2415.</a></li><li><a class="nounderline abstract_t">Schena FP, Pertosa G. Fibronectin and the kidney. Nephron 1988; 48:177.</a></li><li><a class="nounderline abstract_t">Büyükbabani N, Droz D. Distribution of the extracellular matrix components in human glomerular lesions. J Pathol 1994; 172:199.</a></li><li><a class="nounderline abstract_t">Altunkova I, Minkova V, Belovezhdov N. Role of fibronectin in immune glomerulonephritis. Nephron 1993; 63:438.</a></li><li><a class="nounderline abstract_t">Lai KN, To WY, Leung JC, et al. Serologic study of immunoglobulin A-fibronectin aggregates in immunoglobulin A nephropathy. Am J Kidney Dis 1996; 27:622.</a></li><li><a class="nounderline abstract_t">Shikata K, Makino H, Morioka S, et al. Distribution of extracellular matrix receptors in various forms of glomerulonephritis. Am J Kidney Dis 1995; 25:680.</a></li><li><a class="nounderline abstract_t">Van Vliet A, Baelde HJ, Vleming LJ, et al. Distribution of fibronectin isoforms in human renal disease. J Pathol 2001; 193:256.</a></li><li><a class="nounderline abstract_t">Zhao HL, Lai FM, Tong PC, et al. Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes. Am J Kidney Dis 2004; 44:1039.</a></li><li><a class="nounderline abstract_t">Ding L, Zhao M, Zou W, et al. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13:113.</a></li><li><a class="nounderline abstract_t">Oomura A, Nakamura T, Arakawa M, et al. Alterations in the extracellular matrix components in human glomerular diseases. Virchows Arch A Pathol Anat Histopathol 1989; 415:151.</a></li><li><a class="nounderline abstract_t">Strøm EH, Banfi G, Krapf R, et al. Glomerulopathy associated with predominant fibronectin deposits: a newly recognized hereditary disease. Kidney Int 1995; 48:163.</a></li><li><a class="nounderline abstract_t">Otsuka Y, Takeda A, Horike K, et al. A recurrent fibronectin glomerulopathy in a renal transplant patient: a case report. Clin Transplant 2012; 26 Suppl 24:58.</a></li><li><a class="nounderline abstract_t">Gemperle O, Neuweiler J, Reutter FW, et al. Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow-up in a large kindred. Am J Kidney Dis 1996; 28:668.</a></li><li><a class="nounderline abstract_t">Tuttle SE, Sharma HM, Bay W, Hebert L. A unique familial lobular glomerulopathy. Arch Pathol Lab Med 1987; 111:726.</a></li><li><a class="nounderline abstract_t">Satoskar AA, Shapiro JP, Bott CN, et al. Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol 2012; 25:709.</a></li><li><a class="nounderline abstract_t">Twal WO, Czirok A, Hegedus B, et al. Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 2001; 114:4587.</a></li><li><a class="nounderline abstract_t">Lomas AC, Mellody KT, Freeman LJ, et al. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem J 2007; 405:417.</a></li><li><a class="nounderline abstract_t">Ohashi T, Lemmon CA, Erickson HP. Fibronectin Conformation and Assembly: Analysis of Fibronectin Deletion Mutants and Fibronectin Glomerulopathy (GFND) Mutants. Biochemistry 2017; 56:4584.</a></li><li><a class="nounderline abstract_t">Dos Reis Monteiro MLG, Custódio FB, de Menezes Neves PDM, et al. A novel single amino acid deletion impairs fibronectin function and causes familial glomerulopathy with fibronectin deposits: case report of a family. BMC Nephrol 2019; 20:322.</a></li><li><a class="nounderline abstract_t">Zhang Z, Kundu GC, Yuan CJ, et al. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 1997; 276:1408.</a></li><li><a class="nounderline abstract_t">Mukherjee AB, Kundu GC, Mandal AK, et al. Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice. Am J Kidney Dis 1998; 32:1106.</a></li><li><a class="nounderline abstract_t">Vollmer M, Krapf R, Hildebrandt F. Exclusion of the uteroglobin gene as a candidate for fibronectin glomerulopathy (GFND). Nephrol Dial Transplant 1998; 13:2417.</a></li><li><a class="nounderline abstract_t">Hildebrandt F, Strahm B, Prochoroff A, et al. Glomerulopathy associated with predominant fibronectin deposits: exclusion of the genes for fibronectin, villin and desmin as causative genes. Am J Med Genet 1996; 63:323.</a></li><li><a class="nounderline abstract_t">Ishimoto I, Sohara E, Ito E, et al. Fibronectin glomerulopathy. Clin Kidney J 2013; 6:513.</a></li><li><a class="nounderline abstract_t">Bürgin M, Hofmann E, Reutter FW, et al. Familial glomerulopathy with giant fibrillar deposits. Virchows Arch A Pathol Anat Histol 1980; 388:313.</a></li><li><a class="nounderline abstract_t">Assmann KJ, Koene RA, Wetzels JF. Familial glomerulonephritis characterized by massive deposits of fibronectin. Am J Kidney Dis 1995; 25:781.</a></li><li><a class="nounderline abstract_t">Aslam N, Singh A, Cortese C, Riegert-Johnson DL. A novel variant in FN1 in a family with fibronectin glomerulopathy. Hum Genome Var 2019; 6:11.</a></li><li><a class="nounderline abstract_t">Hara M, Kusaba T, Ono K, et al. Extraglomerular Vascular Involvement of Glomerulopathy with Fibronectin Deposits. Intern Med 2021; 60:2103.</a></li><li class="breakAll">Sanders PW. Dysproteinemias and amyloidosis. In: Primer of Kidney Diseases, 2nd ed, Greenberg A, Cheung AK, Coffmann TM, et al (Eds), Academic Press, San Diego 1998. p.220.</li><li><a class="nounderline abstract_t">Qiu J, Chi H, Gan C, et al. A high-impact FN1 variant correlates with fibronectin-mediated glomerulopathy via decreased binding to collagen type IV. Pathology 2023; 55:498.</a></li><li><a class="nounderline abstract_t">Goldman BI, Panner BJ, Welle SL, et al. Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND). CEN Case Rep 2021; 10:510.</a></li><li><a class="nounderline abstract_t">Wei X, Wang X, Zhang R, et al. Case Report: Recurrent Deposition in Renal Allografts: A Rare Case of Fibronectin Glomerulopathy Overlooked in Native Kidneys. Front Genet 2022; 13:839703.</a></li></ol></div><div id="topicVersionRevision">Topic 3072 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mutations in FN1 cause glomerulopathy with fibronectin deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219110" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A case of familial glomerulopathy with fibronectin deposits caused by the Y973C mutation in fibronectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056061" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601194" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical and morphological features of fibronectin glomerulopathy: a report of ten patients from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620516" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fibronectin Glomerulopathy Caused by the Y973C Mutation in Fibronectin: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29265057" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fibronectin glomerulopathy - A sporadic case with unusual clinical manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815434" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fibronectin requirement in branching morphogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606706" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Plasma fibronectin promotes thrombus growth and stability in injured arterioles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281043" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fibronectin and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8169750" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Distribution of the extracellular matrix components in human glomerular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459880" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Role of fibronectin in immune glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629620" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serologic study of immunoglobulin A-fibronectin aggregates in immunoglobulin A nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538261" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Distribution of extracellular matrix receptors in various forms of glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180174" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Distribution of fibronectin isoforms in human renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558525" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14995004" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2500770" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Alterations in the extracellular matrix components in human glomerular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564073" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Glomerulopathy associated with predominant fibronectin deposits: a newly recognized hereditary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22747478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A recurrent fibronectin glomerulopathy in a renal transplant patient: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158203" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow-up in a large kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2443103" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A unique familial lobular glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282304" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792823" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472576" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28745050" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fibronectin Conformation and Assembly: Analysis of Fibronectin Deletion Mutants and Fibronectin Glomerulopathy (GFND) Mutants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31419955" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A novel single amino acid deletion impairs fibronectin function and causes familial glomerulopathy with fibronectin deposits: case report of a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9162006" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856533" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9761542" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Exclusion of the uteroglobin gene as a candidate for fibronectin glomerulopathy (GFND)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723129" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Glomerulopathy associated with predominant fibronectin deposits: exclusion of the genes for fibronectin, villin and desmin as causative genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26064516" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fibronectin glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7001730" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Familial glomerulopathy with giant fibrillar deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747733" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Familial glomerulonephritis characterized by massive deposits of fibronectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30820325" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A novel variant in FN1 in a family with fibronectin glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33551409" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Extraglomerular Vascular Involvement of Glomerulopathy with Fibronectin Deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33551409" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Extraglomerular Vascular Involvement of Glomerulopathy with Fibronectin Deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36774238" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A high-impact FN1 variant correlates with fibronectin-mediated glomerulopathy via decreased binding to collagen type IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33837952" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35774511" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Case Report: Recurrent Deposition in Renal Allografts: A Rare Case of Fibronectin Glomerulopathy Overlooked in Native Kidneys.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
